drugset / Trial / NCT03801746

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

NCT03801746

Phase 1 Completed 40 enrolled Akebia Therapeutics
RandomizedSequentialOpen-labelBasic science

Summary

This is a Phase 1, two-part, open-label study to evaluate the interaction of cyclosporine, probenecid, and rifampin as perpetrators with vadadustat (victim) in healthy male and female subjects.

Timeline

Start
2018-07-20
Primary completion
2018-08-15
Completion
2018-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 500 mg Oral
Subject Probenecid Small molecule 500 mg Oral
Subject Rifampin Small molecule 600 mg Intravenous
Subject Vadadustat Small molecule 300 mg Oral

Indications

No indication recorded.